This article is more than 5 years old. Information may no longer be current.

VIDEO: Eisai executive highlights key pipeline assets

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Takashi Owa, PhD, chief discovery officer and chief medicine creation officer for Eisai’s oncology business group, spoke with HemOnc Today at ASCO Annual Meeting about the company’s pipeline.

Several of the agents in development are relevant to resistance to current immuno-oncology therapies, Owa said.

“We are very excited about the advancement of these early pipeline assets,” Owa told HemOnc Today.

He also discussed the company’s unique splicing platform, which potentially could lead to the generation of neoantigens.